Skip to main
DNLI
DNLI logo

Denali Therapeutics (DNLI) Stock Forecast & Price Target

Denali Therapeutics (DNLI) Analyst Ratings

Based on 20 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Denali Therapeutics Inc. is poised for growth with an imminent tivi BLA accelerated approval filing, expected to capture significant market share starting in 2026. The company is enhancing its operational efficiencies by moving towards in-house manufacturing for its antibody and enzyme transport vehicles, which is projected to support an increase of 1-2 planned INDs annually through 2027, while maintaining a reasonable operational expense increase of 10-15%. Positive clinical outcomes from recent studies, including improvements in liver volume and cognitive function, alongside a solid performance in R&D expenditures compared to estimates, strengthen the case for Denali's innovative transport-vehicle platform, positioning it favorably within the neurodegeneration therapeutic landscape.

Bears say

Denali Therapeutics Inc. faces significant challenges that may adversely affect its stock outlook, primarily stemming from potential delays or failures in the development and commercialization of its product candidates, which could hinder business prospects and operational results. The discontinuation of the III dose cohort for Elaprase highlights concerns over long-term durability, likely impacting the adoption of gene therapies and delaying revenue generation. Additionally, the company reported a net loss of $114.8 million, raising concerns about its financial stability and prospects in a competitive landscape characterized by uncertain clinical trial outcomes and narrow market penetration capabilities.

Denali Therapeutics (DNLI) has been analyzed by 20 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Denali Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Denali Therapeutics (DNLI) Forecast

Analysts have given Denali Therapeutics (DNLI) a Strong Buy based on their latest research and market trends.

According to 20 analysts, Denali Therapeutics (DNLI) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Denali Therapeutics (DNLI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.